Cargando…

Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design

Ovarian cancer (OC) is highly lethal due to late detection and frequent recurrence. Initial treatments, comprising surgery and chemotherapy, lead to disease remission but are invariably associated with subsequent relapse. The identification of novel therapies and an improved understanding of the mol...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan-Ruide, Ochoa, Christopher J., Zhu, Yichen, Kramer, Adam, Wilson, Matthew, Fang, Ying, Chen, Yuning, Singh, Tanya, Di Bernardo, Gabriella, Zhu, Enbo, Lee, Derek, Moatamed, Neda A., Bando, Joanne, Zhou, Jin J., Memarzadeh, Sanaz, Yang, Lili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558812/
https://www.ncbi.nlm.nih.gov/pubmed/37810241
http://dx.doi.org/10.1016/j.isci.2023.107952
Descripción
Sumario:Ovarian cancer (OC) is highly lethal due to late detection and frequent recurrence. Initial treatments, comprising surgery and chemotherapy, lead to disease remission but are invariably associated with subsequent relapse. The identification of novel therapies and an improved understanding of the molecular and cellular characteristics of OC are urgently needed. Here, we conducted a comprehensive analysis of primary tumor cells and their microenvironment from 16 chemonaive and 10 recurrent OC patient samples. Profiling OC tumor biomarkers allowed for the identification of potential molecular targets for developing immunotherapies, while profiling the microenvironment yielded insights into its cellular composition and property changes between chemonaive and recurrent samples. Notably, we identified CD1d as a biomarker of the OC microenvironment and demonstrated its targeting by invariant natural killer T (iNKT) cells. Overall, our study presents a comprehensive immuno-profiling of OC tumor and microenvironment during disease progression, guiding the development of immunotherapies for OC treatment, especially for recurrent disease.